BioHarvest Sciences Inc. (BHST) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioHarvest Sciences Inc. (BHST) Materials & Commodity Exposure

BioHarvest Sciences Inc. develops and commercializes plant-based ingredients using its proprietary botanical synthesis platform, targeting the nutraceutical and pharmaceutical sectors. Their key product, VINIA, a red grape cell dietary supplement, highlights their focus on science-backed wellness solutions and positions them within the growing market for plant-derived health products.

What Is the Investment Thesis for BHST?

BioHarvest Sciences presents an investment opportunity within the evolving landscape of plant-based nutraceuticals and pharmaceuticals. The company's proprietary botanical synthesis platform offers a potentially disruptive approach to producing plant-derived compounds, addressing supply chain and consistency challenges. With a market capitalization of $32.4M, the company is positioned for growth if it can successfully scale production and expand its market reach. Key value drivers include the continued commercial success of VINIA and the expansion of its CDMO services. The company's gross margin of 59.3% suggests a strong pricing power. However, the negative profit margin of -32.3% indicates that profitability is a key challenge. Upcoming catalysts include potential partnerships with larger pharmaceutical companies and expansion into new geographic markets. Investors should monitor the company's ability to manage costs and achieve profitability as it scales its operations.

Based on FMP financials and quantitative analysis

BHST Key Highlights

Market Cap of $32.4M indicates a small-cap company with potential for high growth but also higher risk.

• Gross Margin of 59.3% demonstrates strong pricing power and efficient production processes.
• Profit Margin of -32.3% highlights the company's current challenges in achieving profitability.
• Beta of 1.40 suggests the stock is more volatile than the market, indicating higher potential risk and reward.
• The company operates in the growing nutraceuticals and pharmaceuticals markets, driven by increasing consumer demand for plant-based health products.

Who Are BHST's Competitors?

BHST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BHST's Key Strengths?

Proprietary botanical synthesis platform technology.

• Sustainable and controlled production of plant-based ingredients.
• Focus on science-backed and clinically proven solutions.
• Presence in both nutraceuticals and pharmaceuticals segments.

What Are BHST's Weaknesses?

Negative profit margin indicates challenges in achieving profitability.

• Small market capitalization makes it vulnerable to market fluctuations.
• Limited brand recognition compared to larger competitors.
• Reliance on the success of VINIA and CDMO services.

What Could Drive BHST Stock Higher?

Potential partnerships with larger pharmaceutical companies to co-develop plant-based therapeutics.

• Expansion into new geographic markets, particularly in Asia-Pacific and Latin America.
• Continued commercialization of VINIA through increased marketing and distribution efforts.
• Expansion of CDMO services by attracting new clients seeking sustainable ingredient sourcing.

What Are the Key Risks for BHST?

Financial-distress signal — its Altman Z-Score of -2.31 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-88.0%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Competition from larger and more established companies in the nutraceutical and pharmaceutical industries.
• Regulatory changes affecting the production and sale of plant-based ingredients.
• Challenges in scaling production and maintaining consistent product quality.
• Dependence on the commercial success of VINIA and CDMO services for revenue generation.

What Are the Growth Opportunities for BHST?

• Expansion of VINIA Sales: BioHarvest can focus on expanding the market reach of VINIA, its red grape cell dietary supplement. The global dietary supplements market is projected to reach $230.73 billion by 2027, offering a substantial opportunity for growth. By increasing marketing efforts and distribution channels, particularly in the United States and Europe, BioHarvest can capitalize on the growing demand for natural health products. Success depends on demonstrating the clinical efficacy of VINIA and building brand awareness.
• Strategic Partnerships in Pharmaceuticals: BioHarvest can leverage its botanical synthesis platform to form strategic partnerships with pharmaceutical companies. The pharmaceutical industry is increasingly interested in plant-derived compounds for drug development. By offering its technology and expertise, BioHarvest can secure lucrative contracts and generate revenue. The timeline for realizing this opportunity depends on the successful completion of clinical trials and regulatory approvals for new drugs.
• Expansion of CDMO Services: BioHarvest can expand its contract development and manufacturing operation (CDMO) services. The global CDMO market is projected to reach $225.2 billion by 2028, driven by the increasing outsourcing of pharmaceutical and biotechnology manufacturing. By offering its botanical synthesis platform, BioHarvest can attract clients seeking a sustainable and efficient source of plant-based ingredients. Success depends on maintaining high-quality standards and competitive pricing.
• Development of New Plant-Based Ingredients: BioHarvest can invest in the development of new plant-based ingredients using its botanical synthesis platform. The market for novel ingredients is constantly evolving, with new compounds being discovered and developed for various health applications. By focusing on research and development, BioHarvest can create new revenue streams and strengthen its competitive position. The timeline for realizing this opportunity depends on the successful identification and development of commercially viable ingredients.
• Geographic Expansion: BioHarvest can expand its operations into new geographic markets. The global nutraceuticals and pharmaceuticals markets are diverse, with varying consumer preferences and regulatory requirements. By carefully selecting new markets and adapting its products and services accordingly, BioHarvest can increase its global reach and revenue. Key markets to consider include Asia-Pacific and Latin America, where demand for natural health products is growing rapidly.

What Are BHST's Competitive Advantages?

• Proprietary botanical synthesis platform technology.
• Ability to grow plant-based ingredients in a controlled and sustainable manner.
• Focus on science-backed and clinically proven therapeutic solutions.
• Established presence in both the nutraceuticals and pharmaceuticals segments.

What Does BHST Do?

BioHarvest Sciences Inc., based in Vancouver, Canada, is a biotechnology company specializing in the development of plant-based ingredients through its proprietary botanical synthesis platform technology. The company was founded with the vision of revolutionizing the production of plant-derived compounds for use in nutraceuticals and pharmaceuticals. This technology allows them to grow the active ingredients found in plants, enzymes, or cells in a controlled environment, offering a sustainable and consistent supply chain. BioHarvest operates through two primary segments: Nutraceuticals and Pharmaceuticals. Their nutraceutical offerings include wellness products, with a focus on VINIA, a red grape cell dietary supplement containing a matrix of polyphenols. The company also provides contract development and manufacturing operation (CDMO) services, leveraging its botanical synthesis platform to produce ingredients for other companies. BioHarvest Sciences operates in both Israel and the United States, reflecting its global ambitions and strategic focus on key markets. The company's approach aims to provide clinically proven therapeutic solutions, differentiating it from traditional agricultural methods and positioning it as an innovator in the biotechnology space.

What Products and Services Does BHST Offer?

• Develops a botanical synthesis platform to grow plant-based ingredients.
• Operates in the nutraceuticals and pharmaceuticals segments.
• Offers wellness products, including VINIA, a red grape cell dietary supplement.
• Provides contract development and manufacturing operation (CDMO) services.
• Leverages its technology to create science-based therapeutic solutions.
• Grows ingredients in plant enzymes or cells in a controlled environment.

How Does BHST Make Money?

• Generates revenue from the sale of its VINIA dietary supplement.
• Provides contract development and manufacturing operation (CDMO) services to other companies.
• Focuses on developing and commercializing plant-based ingredients for nutraceutical and pharmaceutical applications.

What Industry Does BHST Operate In?

BioHarvest Sciences operates within the agricultural inputs sector, specifically targeting the nutraceutical and pharmaceutical industries. The market for plant-based ingredients is experiencing significant growth, driven by increasing consumer demand for natural and sustainable health solutions. This trend is fueled by a growing awareness of the health benefits associated with plant-derived compounds and a desire for alternatives to synthetic drugs. The competitive landscape includes both traditional agricultural companies and other biotechnology firms developing innovative production methods. BioHarvest's botanical synthesis platform positions it as a technology-driven player within this market, potentially offering a competitive advantage in terms of scalability, consistency, and sustainability.

Who Are BHST's Key Customers?

• Consumers seeking natural health and wellness products.
• Pharmaceutical companies looking for plant-derived ingredients for drug development.
• Other companies in the nutraceutical and pharmaceutical industries seeking CDMO services.

Wall Street analysts project BioHarvest Sciences Inc. revenue of about $37.4M for fiscal 2026, with EPS near $-0.53. The estimate reflects 3 contributing analysts.

Quarterly Financial Performance: BioHarvest Sciences Inc.

Revenue for BioHarvest Sciences Inc. came in at $8.8M during Jun 2026, a 3.9% improvement versus the preceding quarter. The company recorded a net loss of $3.7M, with diluted EPS of $-0.16. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Basic Materials. Across the four most recent quarters, BHST averaged $-0.14 in diluted EPS.

BHST Valuation & Market Position

With a $32.4M market cap, BioHarvest Sciences Inc. sits in the micro-cap segment of the market. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $1.87, that implies approximately 167% upside potential. Relative to its peer group, BHST's quantitative score of 21/100 is below the peer average of 57/100.

Return on equity for BioHarvest Sciences Inc. stands at -88.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.7%, the inverse of the P/E and a quick read on earnings relative to price.

BioHarvest Sciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.31 places it in the distress zone, a signal of elevated financial risk.

BioHarvest Sciences Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 47.1% below estimates on average.

Company Profile

BioHarvest Sciences Inc. operates in the Agricultural - Commodities/Milling industry within the Industrials sector. It is headquartered in Vancouver, CA. The company is led by CEO Zaki Rakib. BHST has traded publicly since 2021.

BHST Financials

BHST Latest News

BHST Analyst Consensus

BHST MoonshotScore

BioHarvest Sciences Inc. Basic Materials Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources